Related references
Note: Only part of the references are listed.Serum iron, Magnesium, Copper, and Manganese Levels in Alcoholism: A Systematic Review
Cezary Grochowski et al.
MOLECULES (2019)
Obesity as a tumour development triggering factor
Agnieszka Budny et al.
ANNALS OF AGRICULTURAL AND ENVIRONMENTAL MEDICINE (2019)
Neural stem cell therapy-Brief review
Cezary Grochowski et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2018)
Antibodies to watch in 2018
Helene Kaplon et al.
MABS (2018)
Monoclonal antibodies in cancer immunotherapy
Ilgin Kimiz-Gebologlu et al.
MOLECULAR BIOLOGY REPORTS (2018)
ATIM-15. A PHASE I TRIAL OF HYPOFRACTIONATED STEREOTACTIC IRRADIATION (HFSRT) WITH PEMBROLIZUMAB AND BEVACIZUMAB IN patients with recurrent high grade gliomas
Solmaz Sahebjam et al.
NEURO-ONCOLOGY (2017)
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Daniel Sanghoon Shin et al.
CANCER DISCOVERY (2017)
EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment
Stefanie Keller et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
OS09.5 Synergistic effect of reirradiation and PD-1 inhibitors in recurrent high-grade gliomas
F. M. Iwamoto et al.
NEURO-ONCOLOGY (2017)
Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma
Manuela Silginer et al.
NEURO-ONCOLOGY (2017)
RANDOMIZED PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: CHECKMATE 143
D. A. Reardona et al.
NEURO-ONCOLOGY (2017)
Ultra high field TOF-MRA: A method to visualize small cerebral vessels. 7 T TOF-MRA sequence parameters on different MRI scanners - Literature review
Cezary Grochowski et al.
NEUROLOGIA I NEUROCHIRURGIA POLSKA (2017)
Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma
Song Xue et al.
ONCOTARGET (2017)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz et al.
CELL REPORTS (2017)
Tumor microenvironment in treatment of glioma
Guijie Li et al.
OPEN MEDICINE (2017)
Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I/II results of ECHO-204.
Raymond P. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: An update.
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab combined with hypofractionated stereotactic irradiation (HFSRT) for patients with recurrent high grade gliomas: A phase I trial (NCT02829931).
Solmaz Sahebjam et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients.
Rachel E. Sanborn et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Accelerated Hypofractionated Radiotherapy in the Era of Concurrent Temozolomide Chemotherapy in Elderly Patients with Glioblastoma Multiforme
Liana Greer et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2017)
Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers
A. Krishnamurthy et al.
DRUGS OF TODAY (2017)
Immunotherapy for non-small cell lung cancer: current concepts and clinical trials
Marissa Mayor et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2016)
PD-L1 expression and prognostic impact in glioblastoma
Edjah K. Nduom et al.
NEURO-ONCOLOGY (2016)
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Lucia Festino et al.
DRUGS (2016)
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Peter J. R. Ebert et al.
IMMUNITY (2016)
PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease
Kuti Baruch et al.
NATURE MEDICINE (2016)
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Ju Yeon Lee et al.
NATURE COMMUNICATIONS (2016)
Glioblastoma Stem-Like Cells: Characteristics, Microenvironment, and Therapy
Yang Yi et al.
FRONTIERS IN PHARMACOLOGY (2016)
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma
Marcel A. Deken et al.
ONCOIMMUNOLOGY (2016)
Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM).
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Safety and antitumor activity of hypofractionated stereotactic irradiation (HFSRT) with pembrolizumab (Pembro) and bevacizumab (Bev) in patients (pts) with recurrent high grade gliomas: Preliminary results from phase I study.
Solmaz Sahebjam et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?
Matthias Preusser et al.
CLINICAL NEUROPATHOLOGY (2015)
Heat shock protein vaccines against glioblastoma: from bench to bedside
Leonel Ampie et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi et al.
LANCET ONCOLOGY (2015)
Mechanisms of action of therapeutic antibodies for cancer
J. M. Redman et al.
MOLECULAR IMMUNOLOGY (2015)
Structural and functional features of central nervous system lymphatic vessels
Antoine Louveau et al.
NATURE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Modulation of cerebral endothelial cell function by TGF-β in glioblastoma: VEGF-dependent angiogenesis versus endothelial mesenchymal transition
Shanmugarajan Krishnan et al.
ONCOTARGET (2015)
Treatment of Elderly Patients With Glioblastoma A Systematic Evidence-Based Analysis
Oren J. Zarnett et al.
JAMA NEUROLOGY (2015)
Immunotherapeutic advancements for glioblastoma
Leonel Ampie et al.
FRONTIERS IN ONCOLOGY (2015)
The PD-1/B7-H1 Pathway Modulates the Natural Killer Cells versus Mouse Glioma Stem Cells
Bo Yuan Huang et al.
PLOS ONE (2015)
被撤回的出版物: Recurrent Glioblastoma: Where we stand(Retracted article. See vol. 6, pg. 153, 2017)
Sanjoy Roy et al.
SOUTH ASIAN JOURNAL OF CANCER (2015)
Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM).
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas
Jing Zeng et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Structure and Interactions of the Human Programmed Cell Death 1 Receptor
Xiaoxiao Cheng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Toll like receptor (TLR)-induced differential expression of microRNAs (MiRs) promotes proper immune response against infections: A systematic review
Seyed Hossein Aalaei-andabili et al.
JOURNAL OF INFECTION (2013)
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay et al.
CANCER DISCOVERY (2013)
Inverse Association between Programmed Death Ligand 1 and Genes in the VEGF Pathway in Primary Clear Cell Renal Cell Carcinoma
Richard W. Joseph et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance
T. E. Taylor et al.
CURRENT CANCER DRUG TARGETS (2012)
The regulation of cysteine cathepsins and cystatins in human gliomas
Boris Gole et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
Tadashi Yokosuka et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
The disturbed blood-brain barrier in human glioblastoma
Hartwig Wolburg et al.
MOLECULAR ASPECTS OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway
R. Bonavia et al.
ONCOGENE (2012)
Cannabinoids inhibit peptidoglycan-induced phosphorylation of NF-κB and cell growth in U87MG human malignant glioma cells
Ryosuke Echigo et al.
ONCOLOGY REPORTS (2012)
Functional cooperativity by direct interaction between PAK4 and MMP-2 in the regulation of anoikis resistance, migration and invasion in glioma
D. Kesanakurti et al.
CELL DEATH & DISEASE (2012)
Cancer Immunotherapy Comes of Age
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Human MxA Protein: An Interferon-Induced Dynamin-Like GTPase with Broad Antiviral Activity
Otto Haller et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2011)
Epidermal growth factor induces matrix metalloproteinase-1 (MMP-1) expression and invasion in glioma cell lines via the MAPK pathway
M. Anand et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G. W. Verhaak et al.
CANCER CELL (2010)
Cetuximab Insufficiently Inhibits Glioma Cell Growth Due to Persistent EGFR Downstream Signaling
Benedikte Hasselbalch et al.
CANCER INVESTIGATION (2010)
Cyclooxygenase-2 Is a Novel Transcriptional Target of the Nuclear EGFR-STAT3 and EGFRvIII-STAT3 Signaling Axes
Hui-Wen Lo et al.
MOLECULAR CANCER RESEARCH (2010)
Glioblastoma-Derived Mechanisms of Systemic Immunosuppression
Allen Waziri
NEUROSURGERY CLINICS OF NORTH AMERICA (2010)
The Presence of IL-17A and T Helper 17 Cells in Experimental Mouse Brain Tumors and Human Glioma
Derek A. Wainwright et al.
PLOS ONE (2010)
Molecular Mechanisms Underlying Effects of Epidermal Growth Factor Receptor Inhibition on Invasion, Proliferation, and Angiogenesis in Experimental Glioma
Jean-Sebastien Guillamo et al.
CLINICAL CANCER RESEARCH (2009)
The EGFRvIII variant in glioblastoma multiforme
Hui K. Gan et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2009)
Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand?
Georg Karpel-Massler et al.
MOLECULAR CANCER RESEARCH (2009)
Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis
Haihao Zhu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
TLR-4, IL-1R and TNF-R signaling to NF-kappa B: variations on a common theme
L. Verstrepen et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2008)
Expression of TLR9 within human glioblastoma
Yuxia Meng et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Angiogenesis in brain tumours
Rakesh K. Jain et al.
NATURE REVIEWS NEUROSCIENCE (2007)
Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma
Paul H. Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling
Luke A. J. O'Neill et al.
NATURE REVIEWS IMMUNOLOGY (2007)
A review of micro- and macrovascular analyses in the assessment of tumor-associated vasculature as visualized by MR
Elizabeth Bullitt et al.
NEUROIMAGE (2007)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Andrew T. Parsa et al.
NATURE MEDICINE (2007)
T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa
Jana Goldmann et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2006)
EGFR targeted therapy - View from biological standpoint
Hongbin Ji et al.
CELL CYCLE (2006)
TLR signaling
T Kawai et al.
CELL DEATH AND DIFFERENTIATION (2006)
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis
HS Phillips et al.
CANCER CELL (2006)
Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274)
SJ Lee et al.
FEBS LETTERS (2006)
Angiogenesis in life, disease and medicine
P Carmeliet
NATURE (2005)
Constitutive and inducible expression of B7 family of ligands by human airway epithelial cells
J Kim et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2005)
B7-homolog I expression by human glioma: a new mechanism of immune evasion
R Wilmotte et al.
NEUROREPORT (2005)
Type I interferons and the innate immune response - more than just antiviral cytokines
PL Smith et al.
MOLECULAR IMMUNOLOGY (2005)
Mechanisms of type-I- and type-II-interferon-mediated signalling
LC Platanias
NATURE REVIEWS IMMUNOLOGY (2005)
The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis
DJ Brat et al.
NEURO-ONCOLOGY (2005)
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis
B Kaur et al.
NEURO-ONCOLOGY (2005)
Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients
AB Heimberger et al.
CLINICAL CANCER RESEARCH (2005)
Adams: Key components in EGFR signalling and development
CP Blobel
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2005)
Structural and functional analysis of the costimulatory receptor programmed death-1
XW Zhang et al.
IMMUNITY (2004)
Interferon-γ:: an overview of signals, mechanisms and functions
K Schroder et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2004)
Molecular mechanisms of glioma invasiveness: The role of proteases
JS Rao
NATURE REVIEWS CANCER (2003)
The blood-brain barrier and its role in immune privilege in the central nervous system
JS Pachter et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2003)
Type I interferon differential therapy for erythroleukemia: specificity of STAT activation
VS Cull et al.
BLOOD (2003)
The brain as an immune privileged site: dendritic cells of the central nervous system inhibit T cell activation
T Suter et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
Novel signal transduction pathway utilized by extracellular HSP70 -: Role of Toll-like receptor (TLR) 2 AND TLR4
A Asea et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
PAI-1 and EGFR expression in adult glioma tumors: Toward a molecular prognostic classification
X Muracciole et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
Epidermal growth factor and pro-inflammatory cytokines regulate the expression of components of plasminogen activation system in U373-MG astrocytoma cells
A Kasza et al.
CYTOKINE (2001)
B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells
SY Tseng et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Up-regulation of urokinase-type plasminogen activator and its receptor correlates with enhanced invasion activity of human glioma cells mediated by transforming growth factor-alpha or basic fibroblast growth factor
T Mori et al.
JOURNAL OF NEURO-ONCOLOGY (2000)
Share Paper
